Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.

NCT NCT05027269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
Lead sponsor
Avidity Biosciences, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 28, 2021
Completion date
February 14, 2023
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

dm1, dystrophy myotonic, myotonic disorders, myotonic dystrophy, myotonic dystrophy 1, myotonic dystrophy type 1 (dm1), myotonic muscular dystrophy, steinert disease